SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will present new clinical data at the 2025 American Academy of Dermatology (AAD) Annual Meeting, which will take place from March 7-11, 2025, at the Orlando Convention Center in Florida. The company will showcase findings from 14 clinical studies that highlight how its well-known brands are using the latest science to influence the Skin Health & Beauty sector. This presentation will include evidence from Kenvue's scientific research alongside other industry insights.
On Wednesday, Kenvue, a consumer health company, announced that it has added three new directors to its board following an agreement with the activist investor Starboard Value.
David Faber from CNBC appears on 'Squawk Box' to share the most recent news updates.
Kenvue has reached an agreement to end its proxy battle with the activist group Starboard, according to sources who spoke to CNBC.
Consumer health company Kenvue (NYSE: KVUE), industrial giant 3M (NYSE: MMM), and oil and gas firm Devon Energy (NYSE: DVN) are currently available at lower prices for several reasons. Let's explore why these three companies might be great value stock options in 2025.
We have just released a list of the 10 Best Spin Off Stocks to Buy Based on Hedge Fund Recommendations. In this article, we will examine how Kenvue Inc. (NYSE:KVUE) compares to other spin off stocks. A corporate spinoff occurs when a company chooses to separate a part of its business into a new entity.
Kenvue (KVUE 0.54%) shares have fallen since it separated from Johnson & Johnson (JNJ 1.13%) in August 2023. However, after over a year of performance data, investors have had the opportunity to adjust to Kenvue operating on its own.
Kenvue, which separated from Johnson & Johnson, has the potential to be a good dividend stock after 2025, even with current economic difficulties and recent earnings shortfalls. The company has well-known brands such as Tylenol and Listerine, and its management plans to save $350 million by 2026 through cost-cutting measures. While Kenvue's valuation and growth outlook are appealing for long-term dividend investors, challenges with cash flow suggest it should be held for the time being.
Out of the ten lowest-priced Dividend Aristocrats, five companies - Franklin Resources, Realty Income, Amcor, Hormel, and Kenvue - are considered good investment options, as their dividends are higher than their share prices. Analysts expect the Top Ten Aristocrat Dogs to see net gains between 15.84% and 46.98% by February 2025, with an average increase of 21.63%. However, ten of these Aristocrats have negative free cash flow margins, which makes them risky investments, including Federal Realty, Kenvue, and PepsiCo.
Kenvue's stock has not done well since it went public, with lower expectations for 2023 and 2024, and little growth expected in 2025. However, the company's well-known brands like Tylenol and Band-Aid, along with support from activist investor Starboard Value, indicate that there is a chance for recovery. While Kenvue has faced challenges from execution problems and outside influences, better marketing and management could lead to growth in the future.